Literature DB >> 3332112

Thalassaemia intermedia.

J S Wainscoat1, S L Thein, D J Weatherall.   

Abstract

Most patients homozygous for beta thalassaemia have beta thalassaemia major, a severe illness requiring regular blood transfusions. However, some homozygotes remain well without regular transfusions and are described by the term thalassaemia intermedia. Three factors have now been identified which may result in beta thalassaemia intermedia: the inheritance of mild beta+ thalassaemia mutations, the co-inheritance of alpha thalassaemia and the inheritance of factors enhancing gamma-globin gene expression. In addition other less common genetic interactions also result in thalassaemia intermedia such as the compound heterozygous state for beta and delta beta thalassaemia. These patients need careful clinical follow up, especially since the complications of hypersplenism and iron overload (even in the absence of blood transfusion) can occur.

Entities:  

Mesh:

Year:  1987        PMID: 3332112     DOI: 10.1016/0268-960x(87)90029-4

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  4 in total

1.  Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis.

Authors:  S Ratip; D Skuse; J Porter; B Wonke; A Yardumian; B Modell
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

2.  Guidelines for the fetal diagnosis of globin gene disorders. Globin Gene Disorder Working Party of the BCSH General Haematology Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 3.  Carrier screening and genetic counselling in beta-thalassemia.

Authors:  Antonio Cao
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia.

Authors:  Tiwaporn Nualkaew; Karine Sii-Felice; Marie Giorgi; Bradley McColl; Julie Gouzil; Astrid Glaser; Hsiao P J Voon; Hsin Y Tee; George Grigoriadis; Saovaros Svasti; Suthat Fucharoen; Suradej Hongeng; Philippe Leboulch; Emmanuel Payen; Jim Vadolas
Journal:  Mol Ther       Date:  2021-05-01       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.